Literature DB >> 11240449

Rare side-effects of fenofibrate.

R Rabasa-Lhoret1, M Rasamisoa, A Avignon, L Monnier.   

Abstract

Fibrates are widely prescribed as hypolipidemic drugs and are considered as safe. We report the case of a 69 year-old woman who probably developed a major allergic reaction following a Fenofibrate prescription (generic form) of 300 mg per day. Clinical features included asthenia, hyperthermia (40.5 degrees C) and slight muscular pain. Biological abnormalities were mildly elevated muscular enzymes and pancytopenia rapidly developed. All bacteriologic, virologic, immune and radiologic investigations were normal. Evolution was spontaneously favorable with Fenofibrate withdrawal. This is the first reported case of major fever and pancytopenia following a Fenofibrate prescription. Adverse effects of Fenofibrate are briefly reviewed and their usual favorable outcomes following drug removal are outlined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240449

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  3 in total

1.  Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy.

Authors:  F Grubisić-Cabo; E Vrdoljak
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock.

Authors:  Eric Wiel; Gilles Lebuffe; Emmanuel Robin; Gaëlle Gasan; Delphine Corseaux; Benoît Tavernier; Brigitte Jude; Régis Bordet; Benoît Vallet
Journal:  Intensive Care Med       Date:  2005-08-16       Impact factor: 17.440

Review 3.  Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail.

Authors:  Shadi Salem Alkhayyat; Hayder M Al-Kuraishy; Ali I Al-Gareeb; Maisra M El-Bouseary; Amal M AboKamer; Gaber El-Saber Batiha; Jesus Simal-Gandara
Journal:  Inflamm Res       Date:  2022-08-08       Impact factor: 6.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.